GlassScriptPhysician profile
Gina Rasnic
NPI 1679924633
$1,416.63
in general payments reported to CMS, 2019-2025
23 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.82 · 2022: $294 · 2023: $146 · 2024: $394 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.80 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $228.34 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $136.04 | 2021-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $104.53 | 2024-2025 | Cobenfy |
| Abbvie INC. | $97.72 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $84.18 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $74.24 | 2021-2025 | Trintellix |
| Tris Pharma INC | $73.49 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $72.85 | 2022-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $51.36 | 2024-2025 | Xelstrym |
| Bausch Health US, LLC | $47.88 | 2024-2025 | Aplenzin |
| Harmony Biosciences LLC | $46.02 | 2024-2025 | |
| Axsome Therapeutics, INC. | $45.71 | 2023-2025 | Sunosi, Auvelity |
| Neos Therapeutics, LP | $32.72 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.46 | 2022-2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.02 | 2022 | |
| Corium, LLC | $23.83 | 2025 | Azstarys |
| Alkermes, INC. | $22.56 | 2022 | |
| Lundbeck LLC | $18.84 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $18.17 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.83 | 2022 | |
| Adlon Therapeutics L.P. | $17.34 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.50 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Rasnic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.